A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
New Onset Generalized Myasthenia Gravis (gMG)
Interventions
BIOLOGICAL:
Efgartigimod PH20 SC
Sponsor
argenx